2017
Ketamine: A Promising Rapid-Acting Antidepressant
Wilkinson S, Ostroff R, Katz R, Krystal J. Ketamine: A Promising Rapid-Acting Antidepressant. 2017, 223-239. DOI: 10.1007/978-981-10-6577-4_16.Peer-Reviewed Original ResearchMood disordersDeficiency hypothesisInitiation of therapyRapid antidepressant effectsRapid acting antidepressantsEvidence-based treatmentsLong-term riskMood disorders researchRelapse prevention strategiesEfficient therapeutic targetMechanism of actionOral antidepressantsAntidepressant effectsGlutamatergic receptorsGlutamatergic systemNovel antidepressantsSingle doseClinical trialsKetamine exposureRelated symptomsLong-term effectsPsychiatric disordersPrevention strategiesTherapeutic targetDrug Administration
2003
Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia
Petrakis IL, O’Malley S, Rounsaville B, Poling J, McHugh-Strong C, Krystal JH, VA Naltrexone Study Collaboration Group. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology 2003, 172: 291-297. PMID: 14634716, DOI: 10.1007/s00213-003-1658-9.Peer-Reviewed Original ResearchConceptsFederal Drug AdministrationSide effectsDrinking daysAlcohol dependenceDouble-blind fashionEfficacy of naltrexoneAbnormal involuntary movementsComorbid alcohol dependenceHeavy drinking daysTreatment of alcoholismSymptoms of schizophreniaRelapse prevention strategiesNegative Symptom ScaleNaltrexone augmentationTime-line follow-back methodNeuroleptic medicationNeuroleptic treatmentEffective medicationsMedication complianceComorbid schizophreniaOutpatient studyWeekly therapyEffective pharmacotherapyConclusionsThese dataInvoluntary movements